208 related articles for article (PubMed ID: 25499288)
1. FOLFOXIRI and bevacizumab in metastatic colorectal cancer.
Rahman A
Lancet Oncol; 2014 Dec; 15(13):e590. PubMed ID: 25499288
[No Abstract] [Full Text] [Related]
2. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
Nipp RD; Ryan DP
Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
[TBL] [Abstract][Full Text] [Related]
3. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab or bevacizumab in metastatic colorectal cancer?
Sclafani F; Cunningham D
Lancet Oncol; 2014 Sep; 15(10):1040-1. PubMed ID: 25088941
[No Abstract] [Full Text] [Related]
5. [Advances in the treatment of metastatic colorectal cancer with bevacizumab].
Longo F; Mansueto G
Tumori; 2006; 92(5):suppl 1-12. PubMed ID: 17168449
[No Abstract] [Full Text] [Related]
6. [A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer].
Kawakami H; Satoh T; Nakagawa K
Nihon Rinsho; 2011 Apr; 69 Suppl 3():439-45. PubMed ID: 22214001
[No Abstract] [Full Text] [Related]
7. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
[TBL] [Abstract][Full Text] [Related]
8. Maintenance treatment in metastatic colorectal cancer.
Chibaudel B; Bonnetain F; Tournigand C; de Gramont A
Lancet Oncol; 2015 Dec; 16(16):e583-4. PubMed ID: 26678202
[No Abstract] [Full Text] [Related]
9. Maintenance treatment in metastatic colorectal cancer.
Simkens LH; van Tinteren H; Punt CJ; Koopman M
Lancet Oncol; 2015 Dec; 16(16):e582-3. PubMed ID: 26678201
[No Abstract] [Full Text] [Related]
10. Maintenance therapy for metastatic colorectal cancer.
Giampieri R; Cascinu S
Lancet Oncol; 2015 Oct; 16(13):1281-2. PubMed ID: 26361970
[No Abstract] [Full Text] [Related]
11. Chemotherapy for metastatic colorectal cancer.
Rosales J; Leong LA
J Natl Compr Canc Netw; 2005 Jul; 3(4):525-9. PubMed ID: 16038643
[TBL] [Abstract][Full Text] [Related]
12. FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).
Aparicio T; Linot B; Le Malicot K; Bouché O; Boige V; François E; Ghiringhelli F; Legoux JL; Ben Abdelghani M; Phelip JM; Faroux R; Dahan L; Taieb J; Bedenne L
Dig Liver Dis; 2015 Apr; 47(4):271-2. PubMed ID: 25677925
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of bevacizumab in Chinese patients with metastatic colorectal cancer.
Zhu LM; Zhao YZ; Ju HX; Liu LY; Chen L; Liu BX; Xu Q; Luo C; Ying JE; Yang YS; Zhong HJ
Asian Pac J Cancer Prev; 2014; 15(16):6559-64. PubMed ID: 25169487
[TBL] [Abstract][Full Text] [Related]
14. FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land.
Ottaiano A; Nasti G; Cassata A; De Stefano A; Caraglia M; Avallone A
Cancer Lett; 2017 Nov; 408():71-72. PubMed ID: 28844712
[No Abstract] [Full Text] [Related]
15. Maintenance treatment in metastatic colorectal cancer - Authors' reply.
Hegewisch-Becker S; Graeven U; Arnold D
Lancet Oncol; 2015 Dec; 16(16):e584-5. PubMed ID: 26678203
[No Abstract] [Full Text] [Related]
16. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
Formica V; Massara MC; Portarena I; Fiaschetti V; Grenga I; Del Vecchio Blanco G; Sileri P; Tosetto L; Skoulidis F; Pallone F; Roselli M
Cancer Biomark; 2009; 5(4):167-75. PubMed ID: 19729826
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.
Cetin B; Kaplan MA; Berk V; Ozturk SC; Benekli M; Isıkdogan A; Ozkan M; Coskun U; Buyukberber S
Asian Pac J Cancer Prev; 2012; 13(3):1059-63. PubMed ID: 22631638
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer.
Park LC; Lee HS; Shin SH; Park SJ; Park MI; Oh SY; Kwon HC; Baek JH; Choi YJ; Kang MJ; Kim YS
World J Gastroenterol; 2012 Mar; 18(10):1104-9. PubMed ID: 22416186
[TBL] [Abstract][Full Text] [Related]
19. Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer.
Afonso S; Viani G; Afonso V; Stefano E; Afonso S
Anticancer Drugs; 2011 Jun; 22 Suppl 2():S21-3. PubMed ID: 21768794
[TBL] [Abstract][Full Text] [Related]
20. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]